再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09688 再鼎医药

未开盘 10-22 16:08:35

17.840

-1.940

-9.81%

最高19.080	最低17.830	成交量444.57万
今开18.890	昨收19.780	日振幅6.32%
总市值203.02亿	流通市值203.02亿	总股本11.38亿
成交额8,089万	换手率0.39%	流通股本11.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":17.84,"timestamp":1792656515008,"preClose":19.78,"halted":0,"volume":4445700,"delay":0,"changeRate":-0.09807886754297276,"floatShares":1138000000,"shares":1138000000,"eps":-1.2559619438719132,"marketStatus":"未开盘","change":-1.94,"latestTime":"10-22 16:08:35","open":18.89,"high":19.08,"low":17.83,"amount":80888070,"amplitude":0.063195,"askPrice":17.84,"askSize":2500,"bidPrice":17.83,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-1.3309848668897581,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792719000000},"marketStatusCode":0,"adr":0,"listingDate":1601222400000,"exchange":"SEHK","adjPreClose":19.78,"openAndCloseTimeList":[[1792632600000,1792641600000],[1792645200000,1792656000000]],"volumeRatio":1.1955434362074204,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"2677873639","title":"港股通创新药急转直下，发生了什么？520880标的指数跌逾4.6%，再鼎医药、康方生物重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2677873639","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677873639?lang=zh_cn&edition=full","pubTime":"2026-10-22 11:01","pubTimestamp":1792638060,"startTime":"0","endTime":"0","summary":"10月22日，港股通创新药修复戛然而止，行情急转直下，港股通创新药ETF华宝标的指数下挫逾4.6%，失守所有均线。最新数据显示，截至最新，港股通创新药ETF华宝标的指数市盈率TTM为33.93倍，已回落至近3年39%分位点，配置性价比凸显。低位吸纳港股通创新药核心资产，关注T+0交易工具——港股通创新药ETF华宝：标的指数100%布局创新药研发类公司，近7成仓位押注创新药研发龙头。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-10-22/doc-iniwaezr5258400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4548","LU2399975544.HKD","LU0348784397.USD","LU0348825331.USD","BK4139","LU1720050803.USD","MEDX","LU0417516571.SGD","BK1161","09926","LU0417516902.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","LU2488822045.USD","BK4585","159992","09688","LU0561508036.HKD","IBBQ","LU0348735423.USD","LU0348783233.USD","LU1961090484.USD","KURE","LU0540923850.HKD","IE00BPRC5H50.USD","BK4531","LU0348766576.USD","BK1574","LU0348767384.USD","LU1794554557.SGD","ZLAB","BK4588","FLHK","LU2476274308.USD","BK4526","LU0417516738.SGD","LU2476274720.SGD","LNGR","520880","LU2778985437.USD","06978","BK1588","LU0634319403.HKD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677984892","title":"再鼎医药盘中跌超5%，ESMO临近国产创新药将披露关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2677984892","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677984892?lang=zh_cn&edition=full","pubTime":"2026-10-22 09:36","pubTimestamp":1792632960,"startTime":"0","endTime":"0","summary":"10月22日，再鼎医药(09688.HK)盘中跌超5%，截至9时34分，跌5.26%，报18.74港元/股，成交额506.01万港元。消息面上，10月21日，前三季度创新药对外技术授权约1300亿美元接近去年全年，2026年 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261022/c680961480.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261022/c680961480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4526","BK4531","BK1588","09688","BK1161","ZLAB","159992","BK4139","LU2488822045.USD","BK1574","06978","BK4585","IBBQ","LNGR","BK4588","MEDX","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677460856","title":"创新药股早盘延续涨势 再鼎医药及云顶新耀均涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677460856","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677460856?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:52","pubTimestamp":1792551120,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端创新药股早盘延续涨势，截至发稿，再鼎医药（09688）上涨5.67%，报19.93港元；云顶新耀（01952）上涨5.21%，报35.56港元；映恩生物-B（09606）上涨2.61%，报173港元；康方生物（09926）上涨3.23%，报94.35港元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-21/doc-inivyaat6202848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK4531","BK4526","BK4585","LNGR","ZLAB","BK1161","IBBQ","BK4548","01952","BK1588","BK4139","06978","LU2488822045.USD","MEDX","BK1574","09688","BK4588","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677646635","title":"港股异动 | 创新药股延续涨势 多项重要数据将于ESMO公布 平台型BD接连落地传递信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2677646635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677646635?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:30","pubTimestamp":1792549810,"startTime":"0","endTime":"0","summary":"国金证券认为，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348767384.USD","LU0634319403.HKD","KCAI","LU0348735423.USD","HK0000500386.USD","LU1720050803.USD","LU0348784397.USD","LU0417516571.SGD","BK1574","IE00BPRC5H50.USD","LU0417516738.SGD","LU0348766576.USD","KURE","BK4585","BK1583","06978","IE00B5MMRT66.SGD","LU0348783233.USD","LNGR","LU0348825331.USD","IBBQ","LU0561508036.HKD","MEDX","IE00B543WZ88.USD","159992","HK0000252152.HKD","LU2543165471.USD","HK0000252160.HKD","09606","BK4588","BK1588","VXUS","LU1794554557.SGD","LU2488822045.USD","LU2476274720.SGD","LU2399975544.HKD","01952","LU0540923850.HKD","BK1161","LU1961090484.USD","09926","LU0417516902.SGD","LU2476274308.USD","LU0348827113.USD","LU2778985437.USD","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677643406","title":"【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2677643406","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677643406?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:16","pubTimestamp":1792545406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指出，创新药前沿技术加速迭代，IO2.0、ADC迭代、自免长效双抗等重塑治疗格局。中国原研资产深度融入全球交易，国际化步入收获期。支付端医保与商保双轮驱动，国谈优化准入，商保目录落地缓解高值药进院约束，本土Biotech净现金流改善、迎来盈亏平衡拐点。海内外政策聚焦真创新，生物类似药温和集采兑现。优质管线梯队完备，百济神州、康方生物、科伦博泰等核心分子加速欧美商业化，创新药板块迎来业绩兑现与国际化重估共振。风险提示：BD受海外地缘政策约束风险；创新药行业竞争加剧风险；医保控费降价不及预期风险；海外流动性收紧风险。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994055","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008368742.USD","02616","159992","BK1574","01877","LU0455707207.USD","LU2097828714.EUR","LU1951186391.HKD","LU0348784397.USD","IE00BPRC5H50.USD","IE00B031HY20.USD","01177","06978","IBBQ","LU0348783233.USD","LU0456846285.SGD","LU0880133367.SGD","600109","LNGR","01801","IE00B0JY6N72.USD","LU0516422366.SGD","LU0540923850.HKD","09688","09926","LU0128526141.USD","BK1589","LU0417516571.SGD","MEDX","09995","BK1141","BK0183","LU0228659784.USD","KURE","02269","LU0516422440.USD","LU0823426308.USD","LU1303224171.USD","LU1226288170.HKD","LU1770034418.SGD","06160","LU1794554557.SGD","KCE","06185","LU1807302812.USD","01093","02142","LU0128522744.USD","LU0588546209.SGD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107128899","title":"再鼎医药（09688）发布提名及企业管治委员会最新章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1107128899","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107128899?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:16","pubTimestamp":1792541765,"startTime":"0","endTime":"0","summary":"2026年10月20日，再鼎医药公告称，公司董事会已正式通过《提名及企业管治委员会章程》。该章程明确了提名及企业管治委员会的宗旨、组成、程序管理以及主要职责，重点内容如下：。委员会的设立旨在履行董事会授予的企业管治及董事提名相关职责。– 委员会成员不少于三名。– 委员会可聘请外部顾问，并由公司提供所需资金。委员会各成员可根据具体情况，对相关事项的重要性及关注程度自行判断。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186432543","title":"异动解读｜再鼎医药盘中上涨5.18%，ZL-1503首个临床数据即将公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1186432543","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186432543?lang=zh_cn&edition=full","pubTime":"2026-10-16 11:11","pubTimestamp":1792120263,"startTime":"0","endTime":"0","summary":"10月16日，再鼎医药盘中上涨5.18%，报18.89港元，成交额4441.79万港元。消息面上，公司日前宣布，评估ZL-1503的首个临床研究数据将首次在美国过敏、哮喘与免疫学会年度科学会议上公布，成为股价走强的直接催化。此次将披露的为ZL-1503 1／1b期首次人体试验在健康志愿者中的结果，内容包括单次给药后的药代动力学数据、不同剂量下AD相关生物标志物的药效动力学数据，以及初步安全性与免疫原性数据。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药盘中走强，ZL-1503临床数据将首发","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109072607","title":"创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109072607","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109072607?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:51","pubTimestamp":1792115499,"startTime":"0","endTime":"0","summary":"港股创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%，百济神州涨超6%，再鼎医药涨近5%，药明合联、药明生物涨超4%，药明康德涨近4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","02268","06160","02162","01952","01548","02359","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675542315","title":"生物医药板块走强 康诺亚-B（02162）涨9.00%、金斯瑞生物科技（01548）涨7.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675542315","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675542315?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:37","pubTimestamp":1792114658,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强，康诺亚-B 涨9.00%，金斯瑞生物科技涨7.53%，百济神州涨5.38%，科伦博泰生物涨5.25%，再鼎医药涨4.46%，君实生物涨3.71%，泰格医药涨3.65%，复宏汉霖涨2.99%。中信建投证券表示，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993835","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","HK0000320264.USD","LU2488822045.USD","LU0828237510.HKD","LU1969619763.USD","BK1576","06990","LU1303224171.USD","XBI","BK4581","LU1251922891.USD","LU0307460666.USD","HK0000320223.HKD","02696","BK1583","01877","BK1588","06160","HK0000165453.HKD","HK0000306685.HKD","LU0588546209.SGD","BK1587","LU1719994722.HKD","01548","LU1770034418.SGD","BK1574","BK4585","HK0000306701.USD","399441","LU0196878994.USD","BK1500","LU0228659784.USD","161726","BK1515","02162","09688","LU2328871848.SGD","KURE","BK4588","BK1161","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675546035","title":"【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2675546035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675546035?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:27","pubTimestamp":1792114033,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，本周制药行业表现一般，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医疗器械及服务板块低值耗材表现较好，多受个股事件催化，科技概念标的调整，港股回购活跃；短期关注招标改善和集采出清，中长期看创新、出海、并购。中药板块跑赢申万医药及大盘，关注红利、创新及“四同药品”、中成药集采政策。生物制品板块跑输医药指数及大盘，AI制药、mRNA肿瘤疫苗概念股回调；南北方ILI%均环比降低，南方检测阳性率提升、北方降低。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","01801","02269","KURE","LU0140636845.USD","LU1226287792.SGD","01093","09995","LU2476274720.SGD","01877","BK1515","06185","LU0348827113.USD","LU0819121731.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU0348767384.USD","LU1951186391.HKD","BK1583","06160","SG9999011746.SGD","02142","LU0979878070.USD","601066","09688","LU0326950275.SGD","LU1251922891.USD","LU0634319403.HKD","159938","LU0417516902.SGD","KCE","BK1610","LU0052750758.USD","01177","LU0181495838.USD","LU0823426480.USD","02616","BK1500","LU0314109678.HKD","LU1226287875.USD","09939","LU0359201612.USD","LU0228659784.USD","09926","BK1141","LU0072913022.USD","LU0128526141.USD","LU0540923850.HKD","LU1242518857.USD","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675953869","title":"纳斯达克中国金龙指数涨超0.5%，再鼎医药涨4.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675953869","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675953869?lang=zh_cn&edition=full","pubTime":"2026-10-15 21:38","pubTimestamp":1792071480,"startTime":"0","endTime":"0","summary":"10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与项飙现场对话！\n名额有限，手慢无。让我们共赴可持续之约！【点击报名】每经AI快讯，10月15日，纳斯达克中国金龙指数涨超0.5%，再鼎医药涨4.11%，百胜中国涨3.29%，亚朵集团涨3.17%，宝尊电商涨2.99%，名创优品涨2.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-10-15/doc-iniviksc8037028.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-10-15/doc-iniviksc8037028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09688","LU2488822045.USD","BK4526","BK4139","BK4585",".HXC","BK1574","BK4588","ZLAB","BK1588","BK1161","BK4548","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675153377","title":"港股早盘持续走低 恒生科技指数大幅下跌2.94% 联想集团（00992）大跌13.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675153377","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675153377?lang=zh_cn&edition=full","pubTime":"2026-10-15 12:13","pubTimestamp":1792037591,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股三大指数早盘持续走低，截至午间收盘，恒生指数下跌1.47%；国企指数下跌1.51%；恒生科技指数大幅下跌2.94%。国恩科技半日涨13.19%，消息面上，据公告显示，集团预期于2026年前9个月取得归属于上市公司股东的净利润约9.5亿-11亿元，同比增长54.45%-78.84%;扣非净利约9.2亿-10.7亿元，同比增长54.14%-79.27%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993772","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","02410","LU2328871848.SGD","LU0890818403.SGD","03431","09688","01378","KCAI","HK0000320264.USD","KTEC","LU0128525689.USD","BK1589","LU0320764599.SGD","TCHI","LU1969619763.USD","03692","06160","80992","BK1191","01258","LU1785774172.SGD","02600","IE0034224299.USD","LU0287142896.SGD","LU0029875118.USD","LU1224709979.USD","KURE","LNVGY","LU0543330483.HKD","01208","LU0588546209.SGD","LU0417516902.SGD","BK1594","LU0359201612.USD","LU1023057109.AUD","06680","03993","LU0862451753.SGD","LU0164880469.USD","00992","LU0572944931.SGD","LU1719994722.HKD","01276","LU2543165471.USD","LU0672654166.SGD","LU0630314457.HKD","VXUS","LU0049112450.USD","BK1526","BK1513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675083374","title":"再鼎医药早盘涨近4% 将于2026 ACAAI会议公布ZL-1503首个临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2675083374","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675083374?lang=zh_cn&edition=full","pubTime":"2026-10-15 11:02","pubTimestamp":1792033320,"startTime":"0","endTime":"0","summary":"模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。据再鼎医药官微消息，10月14日，再鼎医药宣布，评估ZL-1503的首个临床研究数据将首次在美国过敏、哮喘与免疫学会2026年度科学会议上公布。将在ACAAI 2026会议上公布的1/1b期首次人体试验用于健康志愿者的结果，将包括单次给药后的药代动力学数据，以及在不同ZL-1503剂量下AD相关生物标志物的药效动力学数据。此次ACAAI报告还将包括初步的安全性与免疫原性数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-15/doc-inivhpnp8087033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","ZLAB","BK1574","BK4139","BK4526","BK4531","LU2488822045.USD","BK1161","BK4548","09688","BK1588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675710123","title":"港股异动 | 再鼎医药(09688.HK)涨超3% 将于2026 ACAAI会议公布ZL-1503首个临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2675710123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675710123?lang=zh_cn&edition=full","pubTime":"2026-10-15 10:24","pubTimestamp":1792031084,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","09688","BK1588","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675037153","title":"创新药概念走强 百济神州（06160）涨超4% 机构认为板块长期前景改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2675037153","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675037153?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:59","pubTimestamp":1792029581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念走强，截至发稿，百济神州 涨4.11%，翰森制药涨3.14%，中国生物制药涨3.10%，再鼎医药涨2.80%，石药集团涨2.10%，科伦博泰生物涨2.06%。消息面上，里昂发表研究报告指，中国医疗保健板块处周期底部，管线进展有望提振情绪。中国创新资产为世界肺癌大会的重要亮点，料于欧洲肿瘤内科学会大会继续受关注；该行认为，目前各治疗领域的临床领先地位，将塑造未来市场份额。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993745","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1152091168.USD","LU1770034418.SGD","HK0000165453.HKD","LU1251922891.USD","LU1303224171.USD","BK1521","KURE","LU1008478684.HKD","09688","IE00BZ08YT58.USD","LU1813983027.USD","MEDX","01093","LU0307460666.USD","06978","LU0140636845.USD","IE0008368742.USD","LU0067412154.USD","LU0588546209.SGD","LU1719994722.HKD","BK4585","BK1589","BK0239","159992","06160","LU0828237510.HKD","LU2039709279.SGD","LU1951186391.HKD","BK4139","LU1226288253.USD","IE0008369823.USD","BK1515","BK1583","LNGR","LU0314109678.HKD","LU0501845795.SGD","LU1960683339.HKD","LU2328871848.SGD","IBBQ","01177","03692","06990","688235","LU0228659784.USD","LU0072913022.USD","SG9999004220.SGD","ONC","LU1993786604.SGD","BK4588","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675376082","title":"【券商聚焦】中信建投：AI重塑药物研发 2035年全球市场有望破460亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675376082","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675376082?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:00","pubTimestamp":1792026019,"startTime":"0","endTime":"0","summary":"AI深度介入靶点识别、分子设计等药物研发环节，破解传统制药高投入、长周期难题。报告测算，全球AI制药市场2025年规模约24.9亿美元，2035年有望突破460亿美元，CAGR超33%，国内市场具备高增长潜力；科技巨头、药企、CXO等多方入局，海内外多家头部企业完成平台搭建与商业化验证。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","IE00B031HY20.USD","LU0456827905.SGD","LU0516422440.USD","BK1588","LU0128522744.USD","01093","06185","LU0348825331.USD","LU0979878070.USD","QTOC","VTHR","KURE","LU2242644610.SGD","LU0326950275.SGD","BK1500","LU1152091754.HKD","LU1008478684.HKD","09926","KCE","IE00BZ08YS42.EUR","02142","LU0856984785.SGD","LU2778985437.USD","601066","09688","LU0588546209.SGD","BK1141","AGIX","06160","LU0128526141.USD","CHAT","01801","LU0052750758.USD","IBBJ","09995","LU0501845795.SGD","02269","SG9999002562.SGD","LU0456846285.SGD","ARTY","02616","LU1251922891.USD","BK1576","AIPO","LU0029874061.USD","LU0516422952.EUR","01877","LU0051755006.USD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160271136","title":"异动解读｜再鼎医药盘中下跌8.37%，医药板块走低叠加创新药情绪承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1160271136","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160271136?lang=zh_cn&edition=full","pubTime":"2026-10-14 11:08","pubTimestamp":1791947330,"startTime":"0","endTime":"0","summary":"10月14日，再鼎医药盘中下跌8.37%，报17.4港元，成交额5398.89万港元。消息面上，港股医药股当日整体承压，创新药板块受宏观紧缩预期及板块风险偏好回落影响走弱，再鼎医药随板块下挫。当日医药生物板块多数走低，康方生物一度跌超8%，市场同时关注美国9月CPI数据对利率路径定价的影响。再鼎医药所属生物科技行业中，康方生物跌8.71%，信达生物跌2.56%，百济神州跌2.43%，科伦博泰生物跌2.36%，三生制药跌1.9%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再鼎医药随板块走低，创新药情绪承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675235082","title":"纳斯达克中国金龙指数跌超0.5%，禾赛科技跌5.22%，再鼎医药跌3.66%，逸仙电商跌3.52%，天演药业跌3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675235082","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675235082?lang=zh_cn&edition=full","pubTime":"2026-10-13 21:53","pubTimestamp":1791899596,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2778985437.USD","BILI","ADAG","BK4124","BK4139","BK4505","BK4077","09626","BK4510","BK4585","09688","BK4566","BK4503","HXC","BK4588","BK4504","LU2476274308.USD","YSG","BK4554","BK4085","HSAI","ZLAB","BK4548","BK4526","BK4183","BK4531","BK4513","02525","LU2476274720.SGD","BK4563","BK4509","BK4577","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673008141","title":"纳斯达克中国金龙指数跌超0.5%，文远知行跌6.15%，DCX跌5.38%，再鼎医药跌4.94%，宝尊电商跌4.79%，","url":"https://stock-news.laohu8.com/highlight/detail?id=2673008141","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673008141?lang=zh_cn&edition=full","pubTime":"2026-10-08 21:49","pubTimestamp":1791467346,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00800","PONY","BK4023","LU2488822045.USD","PONX","09991","HXC","02026","BK4122","BK4588","BZUN","BK4548","ZLAB","DCX","BK4558","09688","BK4220","BK4585","BK4531","BK4124","BK4609","WRD","BK4502","BK4139","BK4526","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124164242","title":"再鼎医药：RTW Master Fund, Ltd.增持美股","url":"https://stock-news.laohu8.com/highlight/detail?id=1124164242","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124164242?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:24","pubTimestamp":1791451489,"startTime":"0","endTime":"0","summary":"RTW Master Fund, Ltd.于2026年10月7日在联交所场内以每股均价25.6美元买入再鼎医药股份69.65万股，涉资约1783.04万美元，属场内主动交易，即在二级市场直接买卖股份。RTW Master Fund, Ltd.此次增持前持有再鼎医药好仓5662.92万股，占比4.98%；增持后持股量为5732.57万股，好仓比例升至5.04%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":-0.1569},{"period":"3month","weight":0.1599},{"period":"6month","weight":0.0131},{"period":"1year","weight":-0.2189},{"period":"ytd","weight":0.307}],"compareEarnings":[{"period":"1week","weight":-0.0469},{"period":"1month","weight":-0.0858},{"period":"3month","weight":-0.0813},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.1104},{"period":"ytd","weight":-0.1052}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.017355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.068855},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.098942},{"month":4,"riseRate":0.666667,"avgChangeRate":0.061043},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.046017},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004904},{"month":7,"riseRate":0.666667,"avgChangeRate":0.052949},{"month":8,"riseRate":0.666667,"avgChangeRate":0.046005},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038078},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.063384},{"month":11,"riseRate":0.5,"avgChangeRate":0.047251},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.024481}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}